Retatrutide vs Cagrilintide: Which Metabolic Peptide Goes Further?
Quick Answer
Retatrutide and cagrilintide are both injectable peptides researched for metabolic support, but they work through completely different receptor systems. Retatrutide activates three receptor types at once (GLP-1, GIP, and glucagon), while cagrilintide mimics amylin, a hormone that helps regulate satiety and post-meal glucose. They are not direct substitutes, and most researchers would not compare them as if they were.
What Is Retatrutide?
Retatrutide (LY3437943) is a triple agonist developed by Eli Lilly. It activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. No other compound currently in late-stage development hits all three at once.
The GLP-1 component slows gastric emptying and reduces appetite. The GIP component improves insulin sensitivity and appears to amplify GLP-1 effects. The glucagon component increases energy expenditure and promotes fat oxidation. Together, these three actions create a broader metabolic effect than any single-pathway compound.
In Phase 2 trials, the highest-dose group at 12mg weekly showed approximately 24% mean body weight reduction at 48 weeks . That is notably higher than what semaglutide or tirzepatide showed at comparable Phase 2 benchmarks .
Key details:
- Form: subcutaneous injection, once weekly
- Research dose range: 1mg to 12mg weekly
- Evidence level: Phase 2 complete, Phase 3 ongoing
- Receptor targets: GLP-1R, GIPR, glucagon receptor
What Is Cagrilintide?
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin from pancreatic beta cells. It helps slow gastric emptying, promote satiety signals in the brain, and moderate post-meal glucose spikes.
Natural amylin degrades too quickly for therapeutic use. Cagrilintide is engineered for an extended half-life, allowing once-weekly dosing. On its own, cagrilintide shows modest results. The majority of clinical attention comes from its combination with semaglutide (the CagriSema protocol).
In the REDEFINE Phase 3 trials , the CagriSema combination at cagrilintide 2.4mg plus semaglutide 2.4mg weekly showed roughly 22 to 23% mean body weight reduction at 68 weeks . Cagrilintide alone does not produce those outcomes, but it adds meaningful effect on top of GLP-1 agonism through a completely distinct receptor pathway.
Key details:
- Form: subcutaneous injection, once weekly
- Research dose in combination context: 2.4mg weekly
- Evidence level: Phase 3 in combination with semaglutide
- Receptor targets: amylin receptor (AMY), calcitonin receptor
Comparison Table
| Feature | Retatrutide | Cagrilintide |
|---|---|---|
| Type/form | Triple agonist, weekly SC injection | Amylin analogue, weekly SC injection |
| Mechanism | GLP-1R + GIPR + glucagon receptor | Amylin/calcitonin receptor |
| Typical research dose | 1mg to 12mg weekly | 2.4mg weekly in combination |
| Evidence level | Phase 2 complete, Phase 3 ongoing | Phase 3 in combination |
Key Differences
These two peptides share almost no mechanistic overlap. That is worth understanding clearly before trying to compare outcomes.
1. Receptor pathways are entirely separate. Retatrutide works through incretin and glucagon signaling. Cagrilintide works through amylin signaling. The brain regions involved and the downstream hormonal responses are distinct. Side effect profiles also differ as a result.
2. Retatrutide is primarily a standalone compound. Clinical development for retatrutide treats it as a single agent. Cagrilintide, by contrast, is researched almost entirely as a combination partner. Standalone cagrilintide data is limited compared to CagriSema data.
3. Single-agent weight-reduction signal favors retatrutide. The Phase 2 data at 12mg weekly showed roughly 24% body weight reduction . Cagrilintide on its own does not come close to that level. Researchers tracking single-compound performance tend to note this gap.
4. Thermogenesis vs satiety emphasis. Retatrutide's glucagon component specifically drives fat oxidation and energy expenditure, not just appetite suppression. Cagrilintide's primary effect is slowing gastric emptying and promoting satiety signals. Researchers who want a thermogenic component in their protocol see this as a meaningful distinction. Logging both compound selection and response data over time is one reason researchers use tools like DoseVault to spot patterns in their own protocols across multiple cycles.
Can You Stack Them?
No published peer-reviewed research has studied retatrutide and cagrilintide together. This combination is not validated.
Both compounds affect appetite and food intake through different mechanisms. In theory, combining them could layer satiety signals from multiple pathways. In practice, the effect on GI function, blood glucose regulation, and cardiovascular markers is unknown for this pairing.
The risk profile of such a stack has no clinical backing. Anyone considering a combination of peptides affecting metabolic function should consult a licensed clinician first. Self-directed stacking of unvalidated combinations is where most serious adverse events occur in peptide research contexts.
Frequently Asked Questions
What is the main difference between retatrutide and cagrilintide?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, while cagrilintide is a long-acting amylin analogue targeting amylin and calcitonin receptors. They work through entirely different receptor systems.
Can retatrutide and cagrilintide be stacked together?
No published research has studied this specific combination. Both affect appetite and metabolic function through different pathways, but stacking without clinical guidance carries unknown risks. Consult a licensed clinician before combining any peptides.
What research doses are used for retatrutide?
Phase 2 clinical trials used doses ranging from 1mg to 12mg weekly via subcutaneous injection . The 12mg dose group showed the highest weight-reduction outcomes in published trial data.
Is cagrilintide studied on its own or in combination?
Most published research on cagrilintide studies it in combination with semaglutide (the CagriSema combination). Standalone cagrilintide data exists but the combination trials have generated the most clinical attention.
Who Picks Each, and When?
Researchers drawn to retatrutide tend to:
- Want a single-compound protocol with strong standalone Phase 2 data
- Prioritize energy expenditure and fat oxidation alongside appetite reduction
- Be following Phase 3 trial readouts ahead of potential regulatory review
- Have prior experience with GLP-1 class compounds and want to understand what the glucagon agonism adds
Researchers drawn to cagrilintide tend to:
- Want to complement an existing semaglutide-based protocol with an amylin-pathway layer
- Be specifically interested in post-meal glucose modulation via amylin signaling
- Study how distinct hormonal systems interact for metabolic outcomes
- Follow Novo Nordisk's CagriSema regulatory timeline closely
Related
- Retatrutide
- Cagrilintide
- Cagrilintide vs Semaglutide
- Can You Microdose Retatrutide?
- Does Retatrutide Cause Nausea?
- How to Reconstitute Retatrutide
- Peptides for Fat Loss
Disclaimer: This content is for educational purposes only. It is not medical advice. Retatrutide and cagrilintide are not FDA-approved for general use. Always consult a licensed healthcare provider before using any peptide compound.
Built by medical professionals, gym rats, and experienced biohackers
Tracking a peptide protocol means more than remembering what you pinned. Visit DoseVault to log your research compounds, set dose reminders, and keep a clean record of what you are running and how your body responds over time.